Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook
Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer disease clinical trials. The research work analyzes the ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trial trends across countries and companies.
The report focuses on drugs and therapies being evaluated for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials.
Scope of the Report-
The report focuses on drugs and therapies being evaluated for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials.
Scope of the Report-
- Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials across regions
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer
- Both observational and interventional trials analyzed
- Leading companies and universities participating in Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer clinical trials
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 KEY FINDINGS, 2018
2.1 Snapshot
2.2 Overview of Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
3 CLINICAL TRIALS TRENDS TO 2022
3.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Phase
3.2 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Type
3.3 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Recruitment Status
4 COUNTRY LEVEL ANALYSIS
4.1 Region wise Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
4.2 Top 10 Countries conducting Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
4.3 Trials in Emerging and Developing Economies
5 COMPANY LEVEL ANALYSIS
5.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Sponsor Type
5.2 Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors
6 ENROLMENT TRENDS TO 2022
6.1 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by year
6.2 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Phase
6.3 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Trial Type
6.4 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Recruitment Status
7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS
7.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase
7.2 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase
7.3 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase
7.4 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase
8 APPENDIX
8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 KEY FINDINGS, 2018
2.1 Snapshot
2.2 Overview of Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
3 CLINICAL TRIALS TRENDS TO 2022
3.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Phase
3.2 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Type
3.3 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Recruitment Status
4 COUNTRY LEVEL ANALYSIS
4.1 Region wise Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
4.2 Top 10 Countries conducting Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials
4.3 Trials in Emerging and Developing Economies
5 COMPANY LEVEL ANALYSIS
5.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Sponsor Type
5.2 Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors
6 ENROLMENT TRENDS TO 2022
6.1 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by year
6.2 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Phase
6.3 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Trial Type
6.4 Subjects Recruited for Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials by Recruitment Status
7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS
7.1 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase
7.2 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase
7.3 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase
7.4 Ongoing Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Trials- Phase
8 APPENDIX
8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Country
Figure 2: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Phase of Development, 2018
Figure 3: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Status, 2018
Figure 4: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Type, 2018
Figure 5: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials Split by Region, 2000-2018
Figure 6: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Type of Economy, 2018
Figure 7: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Phase, 2018
Figure 8: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Trial Type, 2018
Figure 9: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Recruitment Status, 2018
Figure 10: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Sponsor Type, 2018
Figure 11: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Type of Sponsors
Figure 12: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Leading Sponsors
Figure 1: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Country
Figure 2: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Phase of Development, 2018
Figure 3: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Status, 2018
Figure 4: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Type, 2018
Figure 5: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials Split by Region, 2000-2018
Figure 6: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Type of Economy, 2018
Figure 7: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Phase, 2018
Figure 8: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Trial Type, 2018
Figure 9: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Recruitment Status, 2018
Figure 10: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Sponsor Type, 2018
Figure 11: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Type of Sponsors
Figure 12: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Enrolment by Leading Sponsors
LIST OF TABLES
Table 1: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Sponsor Type, 2018
Table 2: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Economy Type, 2018
Table 3: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Region, 2018
Table 4: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 1: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Sponsor Type, 2018
Table 2: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Economy Type, 2018
Table 3: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials by Region, 2018
Table 4: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
